anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a new subject sugar derivative expressing strong selectin dependent anti-inflammatory action, excellent in stability and safety and useful as an anti-inflammatory agent, etc., and obtained by condensing a sugar having an eliminable group with an alcohol and succeedingly sulfating or phosphating after the condensation. SOLUTION: This new sulfated or phosphated sugar derivative (or its salt) is expressed by formula I [R1 is H, a sulfuric acid ester, a phosphoric acid ester or L-fucose; R2 to R4 are each H, a sulfuric acid ester or a phosphoric acid ester; (l) is 0 or 1; (m) is 0-15 integer; (n) is 0-21 integer]. (e.g. 2- methylpropyl-D-garactopyranoside 3-sulfate, etc.), exhibits strong selectin- dependent anti-inflammatory action, is excellent in safety and preservation stability and useful for curing and preventing ARDS, sepsis, rheumatism, shock and nephritis. The compound is obtained by reacting a sugar of formula II (X is an eliminable group; Ac is acetyl) with a compound of formula III, then eliminating protecting groups and sulfating or phosphating hydroxyl groups.
Methamphetamine is a drug that causes excess amounts of the neurotransmitters dopamine and norepinephrine to be released into the brain. This overload produces unusual alertness and feelings of elation. When the body undergoes methamphetamine withdrawal, it experiences a reduction in dopamine and norepinephrine. Bupropion is an antidepressant used for the treatment of depression and smoking cessation. Because it functions by increasing the release of dopamine and norepinephrine in the brain, bupropion is likely to decrease the negative effects of methamphetamine withdrawal. The purpose of this study is to evaluate the efficacy of bupropion combined with contingency management (CM) and cognitive behavioral counseling (CBT) as a means of treating methamphetamine dependence.

An initial 2-week screening process will involve participants providing urine samples and completing physical and psychological assessments. If deemed eligible for the remainder of this double-blind study, participants will be randomly assigned to receive either bupropion or placebo over the course of 12 weeks. Participants in both the bupropion and placebo groups will receive contingency management and cognitive behavioral counseling. Participants will report to one of two clinical research sites three times per week. At each visit, participants will be examined by the study staff, provide a urine sample, and receive individual cognitive behavioral counseling sessions. At the end of 12 weeks, treatment will be stopped. Participants will return to the study site 30 days later for evaluation and to be assessed for any possible lingering side effects.
Sociodemographic and lifestyle factors (sleep, physical activity, and sedentary behavior) may predict obesity risk in early adolescence; a critical period during the life course. Analyzing data from 2971 participants (M = 11.94, SD = 0.64 years) wearing Fitbit Charge HR 2 devices in the Adolescent Brain Cognitive Development (ABCD) Study, glass box machine learning models identified obesity predictors from Fitbit-derived measures of sleep, cardiovascular fitness, and sociodemographic status. Key predictors of obesity include identifying as Non-White race, low household income, later bedtime, short sleep duration, variable sleep timing, low daily step counts, and high heart rates (AUCMean = 0.726). Findings highlight the importance of inadequate sleep, physical inactivity, and socioeconomic disparities, for obesity risk. Results also show the clinical applicability of wearables for continuous monitoring of sleep and cardiovascular fitness in adolescents. Identifying the tipping points in the predictors of obesity risk can inform interventions and treatment strategies to reduce obesity rates in adolescents.
BACKGROUND: Although infrequent, Sydenham's chorea (SC) may occur as a result of injury to the basal ganglia in children with acute rheumatic fever (ARF) secondary to group A Streptococcal infection. Certain hallmarks of SC, such as movement disorders, could be utilized as a predictive marker for carditis. The present study aimed to investigate neurologic and cardiologic symptoms in children with suspected SC after ARF.
METHODS: All children aged 5-16 who were admitted at Shahid Madani Pediatric Hospital (Tabriz, Iran), with an initial diagnosis of ARF and SC between 2009 and 2022 were included for echocardiographic assessment and prospective follow-up within 6 and 12 months after the start point. The pattern and severity of valvulopathy, as well as the prevalence of Jones criteria for rheumatic fever, were used to assess the effect. The collected data were analyzed using SPSS Statistics software (version 22.0) using Chi square and Fisher's exact tests. P<0.05 was considered statistically significant.
RESULTS: The study enrolled 85 children, 36 girls and 49 boys, with a mean age of 9.7±2.7. On the first echocardiography, 42.4% of patients had mitral valve regurgitation (MR), with a predominance of female patients (P=0.04). Of those diagnosed with SC (12 girls and 6 boys), 66.7% showed cardiac involvement, with a higher prevalence of MR in both sexes (P=0.04). The pattern of cardiac involvement after 6 months was significantly different between the groups (P=0.04). However, no such difference was observed during the one-year follow-up (P=0.07). Female sex was found to have a significant relationship with SC localization (P=0.01).
CONCLUSION: In addition to its neurological manifestations, SC can be associated with clinical or subclinical cardiac valve dysfunction that might last for more than a year. In addition to attempting early detection and appropriate management, a precise cardiac and neurologic assessment during admission and follow-up is recommended.A preprint version of this manuscript is available at DOI: 10.21203/rs.3.rs-772662/v1 (https://www.researchsquare.com/article/rs-772662/v1).
Participants and Clinical Examinations: Unscreened, non-pregnant women 35-65 years of age are enrolled at three closely located clinical sites in Khayelitsha, South Africa. All women provide informed consent, receive counseling for confidential HIV serotesting, a questionnaire, a pregnancy test if not postmenopausal, anonymous HIV serotesting, and a vaginal speculum examination by nurses trained in visual inspection of the cervix with acetic acid (VIA). Cervical specimens are obtained for testing for N. gonorrhea, Chlamydia trachomatis and high-risk types of HPV, and cytology. The cervix is washed with 5% acetic acid and inspected for gross abnormalities or areas of acetowhitening and a 35 mm. photograph taken. Women with significant cervicitis or vulvovaginitis are treated using the syndromic approach. N. gonorrhea or Chlamydia trachomatis positive women receive appropriate therapy. A positive VIA examination is defined as any acetowhite lesion and no attempt is made to differentiate the acetowhitening of metaplasia from CIN. Women with lesions suspicious for cancer, large acetowhite lesions extending over 70% of the cervix or into endocervical canal, and 374 unsuitable for cryotherapy due to severe atrophy, polyps, cervix distorted, cervix not adequately visualized are excluded. These women are referred to colposcopy.

Women are asked to return 2-6 days later for randomization to either: (1) HPV arm in which all HPV DNA positive women receive cryotherapy; (2) VIA arm in which all VIA positive women receive cryotherapy; and (3) a delayed evaluation arm in which women are followed untreated, irrespective of HPV or VIA status. Randomization is done at a patient level using a computer-generated randomization schedule with arm assignments provided to the clinics in sealed envelopes. Cryotherapy is performed by a nurse using N2O and a cryosurgical unit (Wallach Surgical Devices, Orange, CT) using two 3-minute freezes. Cytology results are not available at the time of cryotherapy. Both treated and untreated women are asked to return at 4 weeks for a questionnaire.

At 6 months, colposcopy is done by a physician blinded to arm and clinical information. All acetowhite lesions are biopsied and all have an endocervical curettage. Women with CIN 2+ are treated with LEEP. Examinations in women who became pregnant during the study are postponed until three months post-partum. Blood for anonymous HIV serotesting is obtained. All women who were HPV or VIA-positive at enrollment and a subset who were HPV and VIA-negative (all women enrolled in 2002) are scheduled for repeat colposcopy at 12 months, 24 months and 36 months post-randomization. At these visits, cervical samples are collected and colposcopy and biopsy if indicated is performed.

Laboratory Testing: HPV testing is done using the Hybrid Capture 2 HPV DNA assay and high-risk probe mixture (Digene Corporation, Gaithersburg, MD) at the University of Cape Town. Biopsies are processed at Columbia University and blindly evaluated by a single pathologist.
As the clinical course of systemic sclerosis (SSc) varies widely, prognostic indicators have been sought to predict the outcomes of individual patients. Racial differences in SSc render it necessary to validate prognostic indicators in different patient cohorts. In this study, we aimed to assess clinical and laboratory parameters in Japanese patients with early-stage SSc with diffuse cutaneous involvement and/or interstitial lung disease, and identify predictive factors for disease progression. We performed multivariate analyses of baseline clinical information to estimate symptoms 4 years later in Japanese patients with diffuse cutaneous SSc and/or SSc with interstitial lung disease. Patients were enrolled in the study within 5 years of disease onset at 10 Japanese SSc centers. Over 12 years, 115 patients followed up for 4 years were included in this study. The modified Rodnan skin score (mRSS) at 4 years correlated with the baseline mRSS and finger-to-palm distance, defined as the average length from the distal tip of the fourth finger to the distal palmar crease. The percentage predicted vital capacity (%VC) in year 4 positively and negatively correlated with initial %VC and the presence of anti-topoisomerase I antibodies, respectively. The Health Assessment Questionnaire Disability Index (HAQ-DI) at 4 years was positively and negatively associated with baseline HAQ-DI and %VC, respectively. The occurrence of digital ulcers within 4 years was associated with the initial presence of digital ulcers, finger-to-palm distance, and the presence of digital pitting scars and anti-topoisomerase I antibodies. This study identified several factors that may predict the progression of early-stage SSc in Japanese patients. Finger-to-palm distance may be a useful tool for predicting the progression of skin thickening and the development of digital ulcers in the early stages of severe SSc, but larger, long-term prospective studies are needed to confirm our findings.
The invention mainly relates to a Shuanghuanglian liquid preparation and a method for measuring the content thereof. The Shuanghuanglian liquid preparation mainly comprises scutelloside, forsythin, chlorogenic acid, and the like, and the adverse reaction thereof is mainly shown in anaphylactic shock, erubescent skin and exanthemata, etc. The invention provides the Shuanghuanglian liquid preparation containing proper chlorogenic acid, scutelloside, forsythin and other effective components, and not only has ideal therapeutic effect, but also reduces the occurrence of the anaphylactic reaction. The invention also provides the method for measuring the content of the Shuanghuanglian liquid preparation; during the application of the measurement method of the invention, only one moving phase is needed to simultaneously measure the content of the five effective components, i.e. the scutelloside, the forsythin, the chlorogenic acid, luteoloside and wogonin. The method not only obviously improves the measurement efficiency, but also effectively reduces the measurement cost.
The present invention discloses a tumor invasion and metastasis resisting function and application of venin cysteine proteinase inhibitor, which belongs to the field of medical biology. Sv-Cystatin cDNA is designed and synthesized and is cloned to a pPICZ alpha A carrier according to 99 amino acid sequences of the cystatin proteine of Chinese cobra venin. Pichia pastoris is converted, and the engineering bacteria GS115-sv-cystatin with stabilization and high express is screened. After inducing expression and purification, external biologic activity experiments indicate that the sv-cystatin recombination protein has the functions of inhibiting papain activity and obviously inhibiting tumor cell invasion and transference. The present invention also builds a pcDNA-sv-cystatin eukaryotic expression carrier. Internal experiments also show that the sv-cystatin can obviously inhibit tumor invasion and metastasis. The present invention is used for preventing and treating tumor invasion and metastasis, and the applying foreground is wide.
All subjects will continue to receive their prescribed Tysabri® 300 mg IV infusions at their approved infusion sites. The patients will receive Tysabri at standard intervals (28-days) except during the pre-planned dose interruption of 2 consecutive skipped doses.
Desvenlafaxine extended-release tablet for oral administration contains desvenlafaxine succinate, a structurally novel SNRI for the treatment of MDD. Desvenlafaxine (O-desmethylvenlafaxine) is the major active metabolite of the antidepressant venlafaxine, a medication used to treat major depressive disorder.

Desvenlafaxine is designated RS-4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol and has the molecular formula of C16H25NO2 (free base) and C16H25NO2•C4H6O4 (succinate anhydrous). Desvenlafaxine succinate anhydrous has a molecular weight of 381.48. The structural formula is shown below. 

Desvenlafaxine succinate, USP is a white to off-white crystalline powder that is soluble in water and slightly soluble in tetrahydrofuran. The solubility of desvenlafaxine succinate is pH dependent. Its octanol:aqueous system (at pH 7) partition coefficient is 0.21. 

Desvenlafaxine is formulated as an extended-release tablet for once-a-day oral administration.

Each tablet contains 37.92 mg or 75.84 mg or 151.67 mg of desvenlafaxine succinate equivalent to 25 mg or 50 mg or 100 mg of desvenlafaxine, respectively. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, stearic acid, talc, titanium dioxide and xanthan gum. 

Additionally, each 25 mg tablet contains iron oxide red and iron oxide yellow and each 100 mg tablet contains FD&C yellow # 6 aluminium lake and FD&C red # 40 aluminium lake.
Cohort 2, only. 8 mg Loperamide given orally once in 1 of 4 study periods.
The present invention provides a nucleic acid sequence comprising one or more selected from the group consisting of the sequences SEQ ID NO. 1-7 and the complements thereof, said nucleic acid sequence being derived from a plant, seed or cell comprising the maize event LP026-4, a representative sample of seed comprising said event having been deposited under accession number CCTCC NO. P202209. The transgenic corn event LP026-4 of the invention is not only well resistant to ingestion by lepidopteran pests, but also is tolerant to glyphosate-containing agricultural herbicides. The maize plant with the double characters has the following advantages: the economic loss caused by lepidopteran pests is avoided; corn crops that can tolerate the common commercial herbicide glyphosate; the corn yield is not reduced; enhancing breeding efficiency, enabling the use of molecular markers to track transgene inserts in the breeding populations and their offspring. Meanwhile, the detection method provided by the invention can rapidly, accurately and stably identify the existence of the plant material derived from the transgenic corn event LP 026-4.
PURPOSE:The titled remedy, containing a streptothricin group, having the anticoccidial activity, and useful as a preventing agent and remedy for poultry coccidiosis with low toxicity. CONSTITUTION:An anticoccidial agent containing a streptothiricin group, e.g. streptothricin, as an active constituent. The coccidiosis is a disease caused by parasitic protozoa belonging to the genus Eimeria, and buquinolate, etc. is known as a remedy for the disease in the past. However, drug-resistant strains appeared. The streptothricin group has not only improved anticoccidial activity but low toxicity to the poultry. The streptothricin group antibiotic substance is prepared by cultivating a microorganism, e.g. Streptomyces lavendulae ATCC 8664, belonging to the genus Streptomyces, and having the ability to produce  the streptothricin group antibiotic substance by the ordinary method.
On the day of the operation, patients underwent preoperative lymphoscintigraphy after the intratumoral injection of a Tc-99m phytate 1 mCi in 0.1-0.2 mL 0.9% NaCl under ultrasonographic guidance. Total thyroidectomy or lobectomy with central neck dissection preceded SLN detection to avoid interference by primary tumor radioactivity. After total thyroidectomy or lobectomy, the dissections were performed toward the internal jugular chain beneath the sternocleidomastoid muscle. A handheld, collimated gamma probe and lymphoscintigraphy were used to scan the lateral compartments (through skin and under the SCM) for "radioactive" lymph nodes. Removed SLNs were submitted immediately for frozen biopsy. If any of the SLNs were positive for metastasis on the frozen sections, MRND was performed immediately. In cases for which the frozen section was negative but the final pathology report detailed microscopic positivity in the lateral sentinel nodes, RAI ablations were performed without additional MRND.
In this study of 30 patients, 22 females and 8 males, 60 fully impacted lower wisdom teeth were extracted bilaterally and in the same position. One of the bilaretal teeth of the patients was randomly selected and mefenamic acid was used as a drug to see post operative effects after extraction of impacted 3rd molars in the study group.
BACKGROUND: Over the last decade, microsurgical soft-tissue transfer became the gold standard for various reconstructions throughout the body. Continuous improvement of instruments and surgical techniques, such as intraoperative indocyanine green angiography (ICG-A), allowed for a very high success rate. This study aimed to assess and validate the role of a standard intraoperative ICG-A in free and pedicled flap surgery to improve overall outcomes.
PATIENTS AND METHODS: From April 2018 to April 2023, 400 consecutive patients who underwent reconstruction using free and pedicled flaps were enrolled. ICG-A was always performed in a free flap after flap elevation, after microsurgical anastomosis, immediately after the flap inset, and after wound closure. In the pedicled flap, the sequential procedure was performed after flap elevation, flap inset, and wound closure.
RESULTS: All 400 patients who underwent flap reconstruction using intraoperative ICG-A had an extremely low incidence of necrosis (0.75% partial necrosis among free and pedicled flaps) and reoperation for perfusion-related complications (0.75% due to acute ischemia and 0.50% due to flap congestion). Minor complications, such as hematoma, seroma, wound dehiscence, and wound infections, were managed with a second operation. No flaps were lost, and all patients were successfully treated.
CONCLUSIONS: This study showed how systematic multistep ICG-A for intraoperative assessment of free and pedicled flap perfusion can significantly reduce the complication rate, including flap loss and re-exploration surgeries, in a time- and cost-effective manner.
The present invention relates to a novel absorbing, photoimageable and aqueous developable positive-working antireflective coating composition comprising a photoacid generator and a polymer comprising at least one unit with an acid labile group and at least one unit with an absorbing chromophore. The invention further relates to a process for using such a composition. The present invention also relates to a novel absorbing, photoimageable and aqueous alkali developable positive-working antireflective coating composition comprising a polymer comprising at least one unit with an acid labile group, a dye and a photoacid generator. The invention further relates to a process for using such a composition. The invention also relates to a novel process for forming a positive image with a positive photoresist and a novel photoimageable and aqueous developable positive-working antireflective coating composition, where the antireflective coating comprises a polymer comprising an acid labile group. The invention further relates to such a composition. The invention also relates to a process for imaging a photoimageable antireflective coating composition.
PURPOSE: New colchicine substitutes which can be produced by molecules by fictionalizing the C7 to ketone or fictionalizing the amino group are provide which have a marked antiblastic activity both on the normal cancer cells and on the chemoresistant phenotype. CONSTITUTION: The compound(I) relates to colchicine and thiocolchicine derivatives which can be obtained from these molecules by functionalization of the C7 to ketone or functionalization of the amino group. In formula, R is methoxy or methylthio, R1 is C1-6 straight or chained alkyl or alkenyl, cyclic or heterocyclic molecular, saturated or unsaturated mono or dicarboxyl or acyl residual group of amino acid or beta-di-glucose or 6-deoxygalactose residual group. The compounds have a marked antiblastic activity both on the normal cancer cells and on the chemoresistant phenotype. The compounds can be administered both by injection and orally. Also described is a compound(II).
To evaluate the status of the pituitary-adrenal axis in the differentiation of a pituitary source from an ectopic source of excessive ACTH secretion, a corticorelin test procedure requires a minimum of five blood samples.

### Procedure

  1. Venous blood samples should be drawn 15 minutes before and immediately prior to ACTHREL® administration. The ACTH baseline is obtained by averaging the values of the two samples.

  2. Administer ACTHREL® as an intravenous infusion over a 30 to 60- second interval at a dose of 1 mcg/kg body weight. Higher doses are not recommended (see PRECAUTIONS and ADVERSE REACTIONS).

  3. Draw venous blood samples at 15, 30, and 60 minutes after administration.

  4. Blood samples should be handled as recommended by the laboratory that will determine their ACTH content. It is extremely important to recognize that the reliability of the ACTHREL® test is directly related to the inter-assay and intra-assay variability of the laboratory performing the assay.




Cortisol determinations may be performed on the same blood samples for the same time points as outlined above. The blood sample handling precautions noted for ACTH should be followed for cortisol.